For Bayer, specifically, the way the Xarelto chips have fallen is quite favorable. In the EU, where Bayer owns 100% of the commercial rights, Xarelto is now approved* for all major indications: AF/stroke prevention, VTE prevention, and acute VTE treatment. US approval for AF/stroke prevention remains in doubt and no US submission has even been made in acute VTE treatment; however, Bayer has only 30% of the commercial rights for Xarelto in the US—JNJ has the rest.
*Pending rubber-stamping for the indications endorsed by the CHMP today.
Market Data 
Markets 
AI
